Effect of matrigel on human extravillous trophoblasts differentiation: modulation of protease pattern gene expression.
The human placenta is characterized by extensive trophoblast invasion of the uterus. Indeed, extravillous cytotrophoblast cells invade the decidua and the upper third of uterine spiral arteries in the myometrium. This invasion is reflected in situ by the expression of specific markers. In order to study this invasion process, we have established an in vitro culture model of human extravillous trophoblast isolated from first trimester chorionic villi. The aim of this study was to investigate the effect of a composite matrix, the Matrigel required for the culture of this homogenous population of extravillous trophoblasts (EVCT), on their in vitro differentiation. The effect of Matrigel was studied on different markers characterized by immunocytochemistry and by real-time polymerase chain reaction assay of transcripts. In addition, the expression of 12 different matrix metalloproteases and their inhibitors were investigated. We show that human extravillous cytotrophoblasts acquire an invasive phenotype on Matrigel associated with a specific pattern of protease gene expression. This in vitro model will be of interest to study the cellular mechanisms involved in abnormal trophoblast invasion observed in poor placentation and preeclampsia.
Tarrade
Anne
A
INSERM 427, Laboratoire de Microscopie Electronique, Laboratoire de Génétique Moléculaire (MV), Faculté des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France.
Goffin
Frederic
F
Munaut
Carine
C
Lai-Kuen
René
R
Tricottet
Viviane
V
Foidart
Jean-Michel
JM
Vidaud
Michel
M
Frankenne
Francis
F
Evain-Brion
Danièle
D
D001483:Base Sequence; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D002455:Cell Division; D002478:Cells, Cultured; D002824:Chorionic Villi; D003094:Collagen / Q000494:pharmacology*; D004338:Drug Combinations; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007797:Laminin / Q000494:pharmacology*; D020782:Matrix Metalloproteinases / Q000187:drug effects / Q000235:genetics*; D008969:Molecular Sequence Data; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011509:Proteoglycans / Q000494:pharmacology*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000187:drug effects / Q000235:genetics; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000187:drug effects / Q000235:genetics; D019717:Tissue Inhibitor of Metalloproteinase-3 / Q000187:drug effects / Q000235:genetics; D014327:Trophoblasts / Q000166:cytology / Q000187:drug effects / Q000502:physiology*
D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; D019715:Tissue Inhibitor of Metalloproteinase-1; D019717:Tissue Inhibitor of Metalloproteinase-3; C059485:matrigel; D019716:Tissue Inhibitor of Metalloproteinase-2; D003094:Collagen; D020782:Matrix Metalloproteinases